Olezarsen for familial chylomicronemia syndrome in children and teens
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This study tests a new medicine called olezarsen to lower very high triglycerides (fats) in the blood of children and teenagers with familial chylomicronemia syndrome (FCS), a rare genetic condition. The goal is to reduce the risk of pancreatitis and other complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- The child must be between 2 and 17 years old (with parent or guardian consent).
- A confirmed genetic diagnosis of familial chylomicronemia syndrome (FCS) is required.
- Fasting triglyceride levels must be at least 880 mg/dL (about 10 mmol/L) at screening.
- The child must be willing to fast for at least 10 hours before certain blood tests.
- No recent pancreatitis, major surgery, or use of other investigational drugs within the specified timeframes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational medication, MAR001, to see if it can lower high levels of fats in the blood (triglycerides and remnant cholesterol) linked to heart disease. If you have these conditions, this treatment might help reduce your risk.
This trial tests a new gene-editing treatment (CS-121) for children and teens with a rare inherited condition called Familial Chylomicronemia Syndrome (FCS). It aims to lower very high triglyceride levels and reduce the risk of pancreatitis.
This study tests a new gene-editing treatment called CS-121 for people with FCS whose triglycerides remain very high despite standard therapy. It aims to lower triglyceride levels by editing the APOC3 gene.
This trial tests a new medicine called plozasiran that may lower very high triglyceride levels, which can reduce the risk of pancreatitis. It is for people with severe hypertriglyceridemia or a rare genetic condition called FCS.
This trial tests if a new medicine, lerodalcibep, can safely lower cholesterol in children ages 6 to 17 who have a genetic condition called heterozygous familial hypercholesterolemia (HeFH). It aims to help children whose cholesterol stays high despite taking standard cholesterol-lowering drugs.
This study tests an experimental medicine called zodasiran in teenagers who have a rare inherited condition that causes very high cholesterol. The goal is to see if it can lower cholesterol levels and reduce the risk of heart problems.
Hear when a new Familial Chylomicronemia Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.